📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
151,859
All-time analysed
43,535
Positive
6,743
Negative
92,744
Neutral
8,769
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
270 announcements match the current filters (relevance ≥ 5).
Prostarm Faces Appeal by Customs Dept Over ₹25.66 Crore Disputed Liability
Prostarm Info Systems has received notice that the Commissioner of Customs, Nhava Seva, has filed an appeal against a previously favorable order. In August 2025, the company had received an Order-in-Original which dropped all proceedings and confirmed no liability regarding a ₹25.66 crore dispute. This appeal, filed before the CESTAT Mumbai, reopens the legal risk associated with the May 2024 Show Cause Notice. The company is currently evaluating its legal strategy to defend its position.
Key Highlights
Customs Department appeals against the August 2025 order that cleared the company of charges.
The ongoing legal dispute involves a significant amount of ₹25.66 crore.
Appeal filed before the Hon’ble Customs, Excise and Service Tax Appellate Tribunal (CESTAT), Mumbai.
The original dispute originated from a Show Cause Notice dated May 21, 2024.
Company is in the process of evaluating further legal course of action.
👀 What to Watch
Investors should monitor the CESTAT proceedings closely as an unfavorable outcome could lead to a significant financial liability. However, the fact that the company won the initial Order-in-Original provides some legal precedent in their favor.
Melstar Clarifies Absence of Segment Reporting Due to Non-Operational Status Under CIRP
Melstar Information Technologies Limited has clarified to the NSE that it did not provide segment-wise financial details because the company was not operational during the reporting periods. The company was under the Corporate Insolvency Resolution Process (CIRP) since October 2019, with a resolution plan by Shivasons Solution India Pvt Ltd approved by the NCLT on November 1, 2023. New management was officially appointed on July 3, 2024, and is currently working on reviving the company's business activities. Financial results for the period from March 2021 to June 2024 were submitted to the exchanges on August 14, 2024.
Key Highlights
CIRP was initiated against the company by NCLT Mumbai on October 3, 2019.
Resolution plan by Shivasons Solution India Pvt Ltd approved by NCLT on November 1, 2023.
New management took control on July 3, 2024, following a Monitoring Agency Meeting.
Company confirmed zero operations during the period, explaining the lack of segment-wise financial data.
Financial results for a 3-year gap (March 2021 to June 2024) were filed on August 14, 2024.
👀 What to Watch
Investors should exercise extreme caution as the company is just emerging from insolvency and has had no operations for several years. Monitor future filings for signs of actual business revival and revenue generation under the new management.
Melstar Clarifies Absence of Segment Data Due to Non-Operational Status Post-Insolvency
Melstar Information Technologies Limited clarified to the NSE that it did not provide segment-wise financial details for the quarter ended June 30, 2024, because the company was not in operations. The company recently emerged from the Corporate Insolvency Resolution Process (CIRP) after the NCLT approved a resolution plan by Shivasons Solution India Pvt Ltd on November 1, 2023. New management was officially appointed on July 3, 2024, and is currently in the process of reviving the company's business activities. Financial results for the long-delayed period of March 2021 to June 2024 were only recently submitted on August 14, 2024.
Key Highlights
NCLT approved the resolution plan by Shivasons Solution India Pvt Ltd on November 1, 2023
New management was inducted into the board on July 3, 2024, to lead the revival process
Company confirms zero operational segments for the quarter ended June 30, 2024
Financial results for the period March 2021 to June 2024 were filed on August 14, 2024
Company was under CIRP since the original NCLT order dated October 3, 2019
👀 What to Watch
Investors should treat this as a high-risk turnaround play and wait for evidence of actual business operations and revenue generation under the new management. The stock remains speculative until the 'revival' phase translates into consistent financial performance.
Sanstar Limited Credit Rating Reaffirmed at 'BBB+; Stable' for ₹113.75 Crore Bank Facilities
CARE Ratings has reaffirmed Sanstar Limited's credit ratings for its bank facilities totaling ₹113.75 crore. The long-term and short-term facilities of ₹95.00 crore were reaffirmed at CARE BBB+; Stable / CARE A2, while specific short-term facilities of ₹18.75 crore were reaffirmed at CARE A2. The review was based on the company's audited operational and financial performance for FY25 and the first nine months of FY26. This reaffirmation indicates a consistent credit profile and stable financial outlook for the company.
Key Highlights
CARE Ratings reaffirmed 'CARE BBB+; Stable / CARE A2' for ₹95.00 crore in long-term/short-term bank facilities.
Short-term bank facilities amounting to ₹18.75 crore were reaffirmed at 'CARE A2'.
The total bank facilities covered under this rating action amount to ₹113.75 crore.
Ratings were reviewed based on audited financial performance for FY25 and 9MFY26.
The 'Stable' outlook suggests that the company is expected to maintain its credit profile in the medium term.
👀 What to Watch
Investors should take this as a sign of financial stability as the company has maintained its creditworthiness. No immediate action is required, but a future upgrade would be a positive signal for lower borrowing costs.
Star Health's AA+ Issuer Rating Reaffirmed by Care Ratings with Stable Outlook
Care Ratings Limited has reaffirmed the credit ratings for Star Health and Allied Insurance Company Limited, signaling continued financial stability. The company's issuer rating remains at 'AA+' with a Stable outlook, while its subordinate debt rating is maintained at 'AA' with a Stable outlook. This reaffirmation reflects the rating agency's confidence in the insurer's creditworthiness and ability to service its debt obligations. The disclosure was made in compliance with SEBI Listing Obligations and Disclosure Requirements.
Key Highlights
Care Ratings reaffirmed the Issuer Rating at AA+ with a Stable outlook.
The rating for the company's subordinate debt was reaffirmed at AA with a Stable outlook.
The announcement confirms compliance with SEBI Regulations 30 and 55.
Ratings reaffirmation indicates a consistent credit profile and financial health for the insurer.
👀 What to Watch
Investors should take this as a positive sign of the company's credit strength and financial stability. No immediate portfolio changes are necessary as the ratings remain unchanged from previous levels.
Blue Star Shareholders Approve Re-appointment of MD B Thiagarajan and New Director Appointments
Blue Star Limited has announced the successful passage of three key leadership resolutions via postal ballot as of March 31, 2026. Shareholders approved the re-appointment of Mr. B Thiagarajan as Managing Director through May 2027, ensuring leadership continuity. Additionally, Mr. Mohit Sud was appointed as Executive Director for the Unitary Cooling Products Group for five years, and Mr. M S Unnikrishnan joined as an Independent Director. These moves strengthen the board and management team for the upcoming fiscal years.
Key Highlights
Re-appointment of B Thiagarajan as Managing Director approved from April 1, 2026, to May 24, 2027
Mohit Sud appointed as Executive Director - Unitary Cooling Products Group for a 5-year term
M S Unnikrishnan appointed as Independent Director for a 5-year term effective January 29, 2026
Total of 1,09,412 shareholders were eligible to vote as of the cut-off date
All resolutions were passed with the requisite majority via remote e-voting
👀 What to Watch
Investors should take confidence in the leadership continuity provided by the MD's re-appointment. Monitor the performance of the Unitary Cooling Products segment under the new Executive Director's leadership.
Star Cement Seeks Reclassification of Chamaria Group (6.05% Stake) to Public Category
Star Cement Limited has applied to the NSE and BSE for the reclassification of 29 members of the Chamaria Group from the 'Promoter' to 'Public' category. This group collectively holds 2,44,60,037 equity shares, representing approximately 6.052% of the company's total share capital as of December 31, 2025. The Board of Directors approved this move on February 6, 2026, confirming the group meets SEBI's regulatory criteria for reclassification. Additionally, the company recently declared a 100% interim dividend of Re. 1 per share.
Key Highlights
Application filed to reclassify 29 members of the Chamaria Group to the Public category.
The group holds 24,460,037 shares, accounting for 6.052% of the total equity.
Application for no-objection was submitted to stock exchanges on February 10, 2026.
Board declared a second interim dividend of 100% (Re. 1 per share) for FY 2025-26.
The reclassification is pursuant to Regulation 31A of SEBI LODR Regulations.
👀 What to Watch
Investors should monitor the change in shareholding structure as it technically increases the public float, though it does not change the company's operational fundamentals. No immediate action is required as this is a regulatory classification update.
Five-Star Business Finance Allots 3.1 Lakh Equity Shares to Promoters at INR 770/Share
Five-Star Business Finance has converted 3,10,000 share warrants into equity shares for its top leadership, including the CMD and CFO. The conversion was executed at a price of INR 770 per share, resulting in a total capital infusion of approximately INR 23.87 crore. Following this allotment, the promoter group's stake has marginally increased from 18.41% to 18.48% on a fully diluted basis. This move demonstrates strong commitment from the leadership team as they exercise their options well within the stipulated 18-month window.
Key Highlights
Allotment of 3,10,000 equity shares at a conversion price of INR 770 per share
Total capital raised through this conversion amounts to approximately INR 23.87 crore
Promoter and CMD Lakshmipathy Deenadayalan acquired 2,60,000 shares, increasing his individual holding
Joint MD & CFO Srikanth Gopalakrishnan converted 50,000 warrants into equity
Total paid-up share capital increased to 29,48,76,168 equity shares
👀 What to Watch
Investors should view this as a positive signal as the top management is increasing their stake at a significant premium, reflecting long-term confidence in the company's business model. No immediate action is required, but it reinforces the stability of the leadership's interest.
Strides Pharma to Acquire Sandoz Generic Brands in Africa for USD 12 Million
Strides Pharma Science, through its subsidiary, has entered into an agreement to acquire and in-license a portfolio of branded generic products from Sandoz across Sub-Saharan Africa. The deal involves an upfront payment of USD 12 million plus variable royalty payments based on future sales. This strategic move targets four key markets—Nigeria, Kenya, Ghana, and Western Sahara—and is expected to position Strides among the top five pharmaceutical companies in the region. The transaction is slated for completion by the end of September 2026.
Key Highlights
Upfront consideration of USD 12 million for acquisition and in-licensing of Sandoz brands.
Targets high-growth Sub-Saharan African markets including Nigeria, Kenya, Ghana, and Western Sahara.
Expected to elevate Strides to a top 5 pharmaceutical player in the SSA region by sales volume.
Portfolio includes established brands in anti-infective, cardiovascular, and dermatology segments.
Transaction includes a corporate guarantee from a Singapore subsidiary to secure payment obligations.
👀 What to Watch
Investors should monitor the integration of these brands as it significantly strengthens Strides' footprint in the African market. The deal is a positive step toward scaling their international branded generics business, though the full financial impact will only be visible after Q2 FY27.
Strides Pharma to Acquire Sandoz Generic Brands in Africa for USD 12 Million
Strides Pharma's subsidiary has entered into a definitive agreement with Sandoz to acquire and in-license a portfolio of branded generic products across Sub-Saharan Africa. The deal involves an upfront payment of USD 12 million plus ongoing royalties, targeting key markets including Kenya, Nigeria, and Ghana. This acquisition is strategically designed to position Strides among the top five pharmaceutical companies in the region. The portfolio includes established brands in anti-infective, cardiovascular, and dermatology segments, with several products generating over USD 1 million in annual sales.
Key Highlights
Upfront consideration of USD 12 Million for acquisition and in-licensing of Sandoz brands
Targeting four key Sub-Saharan Africa markets: Western Sahara, Ghana, Nigeria, and Kenya
Expected to elevate Strides to a top 5 pharmaceutical company in the SSA region by sales
Portfolio includes multiple brands with individual annual sales exceeding USD 1 Million
Transaction closure is anticipated by the end of Q2 FY27 (September 2026)
👀 What to Watch
Investors should view this as a positive strategic move to scale the company's high-growth African business. Monitor the integration of these brands and their contribution to the company's international revenue starting late 2026.
Strides Pharma Acquires Sandoz's SSA Branded Generic Portfolio for $12 Million
Strides Pharma Science's subsidiary has entered into an agreement to acquire and in-license Sandoz's branded generic portfolio across Sub-Saharan Africa for an initial consideration of $12 million. The acquisition spans 13 countries, including key markets like Nigeria, Kenya, and Ghana, focusing on anti-infective, cardiovascular, and dermatology segments. This move is expected to more than double Strides' presence in the region and position it as a top five pharmaceutical player in Sub-Saharan Africa. The transaction is funded via internal accruals and is projected to be EPS-accretive with a closing date expected by the end of Q2 FY27.
Key Highlights
Acquisition of Sandoz's branded generic portfolio in Sub-Saharan Africa for $12 million initial consideration.
The deal more than doubles Strides' regional presence, targeting a top 5 market position in Sub-Saharan Africa.
Portfolio includes multiple brands with individual annual sales exceeding $1 million across three therapeutic segments.
Transaction is expected to be EPS-accretive and is slated for completion by September 30, 2026.
Strategic alignment with 'in Africa for Africa' goal to make Ex-US markets match the scale of the US business.
👀 What to Watch
Investors should monitor the successful integration of these brands as they offer higher-margin branded sales and significant cross-selling opportunities in the fast-growing African market. The low acquisition cost relative to the scale gained makes this a highly capital-efficient growth move.
Five-Star Business Finance Board Approves INR 5,000 Crore Fundraise via NCDs
The Board of Directors of Five-Star Business Finance has approved a significant fundraising limit of up to INR 5,000 Crores. This capital will be raised through the issuance of Non-Convertible Debentures (NCDs) via private placement in one or more tranches. The move is intended to bolster the company's capital base and support its ongoing lending operations. Specific details regarding interest rates and tenures will be disclosed at the time of each allotment.
Key Highlights
Board approved a fundraising limit of up to INR 5,000 Crores through NCDs.
Issuance will be conducted via private placement in one or more tranches or series.
The NCDs are proposed to be listed on stock exchanges to be named at allotment.
The board meeting concluded on March 17, 2026, with immediate approval of the limits.
👀 What to Watch
Investors should monitor the coupon rates of future tranches to assess the company's cost of funds and its impact on net interest margins. The large fundraising limit indicates a strong growth outlook for the company's loan portfolio.
Prostarm Info Systems Declared L-1 Bidder for INR 90.44 Crore WBMSC Contract
Prostarm Info Systems Limited has been declared the L-1 bidder for a significant domestic contract from West Bengal Medical Services Corporation (WBMSC) worth INR 90.44 Crores. The project involves the supply, installation, and commissioning of 6 KVA online UPS systems and batteries across 3,439 healthcare facilities throughout West Bengal. The contract is funded under the XV Finance Commission and is expected to be completed within a 180-day timeframe. This order represents a substantial boost to the company's order book and revenue visibility for the next two quarters.
Key Highlights
Declared L-1 bidder for a contract valued at INR 90.44 Crores from WBMSC Kolkata
Scope covers 3,439 locations including 3,000 Sub Centers and 439 Urban Health Centers
Execution timeline is strictly set at 180 days for supply and commissioning
Project involves 6 KVA single-phase input/output online UPS systems including batteries
👀 What to Watch
Investors should monitor the formal award of the contract and the company's execution progress over the next six months, as this large order could significantly impact short-term earnings.
Prostarm Secures INR 6.71 Cr Order from SAIL for 2 MW Roof Top Solar Project
Prostarm Info Systems Limited has received a Letter of Acceptance (LOA) from Steel Authority of India Limited (SAIL) for a solar infrastructure project. The contract involves the supply, installation, and commissioning of a 2 MW (AC) Roof Top Solar PV System at various plant buildings. Valued at INR 6.71 Crores, the project is slated for completion within a 12-month timeframe. This domestic order from a major PSU enhances the company's credentials in the renewable energy sector.
Key Highlights
Received a Letter of Acceptance from Steel Authority of India Limited (SAIL) worth INR 6.71 Crores
Scope includes supply, installation, and commissioning of a 2 MW (AC) Roof Top Solar PV System
Project execution period is defined as 12 months
The order is domestic and was secured in the normal course of business
👀 What to Watch
Investors should view this as a positive development that strengthens the order book and validates the company's technical capabilities with a major PSU client. Monitor the execution progress over the next 12 months to ensure timely revenue recognition.
Prostarm Secures INR 6.71 Cr Solar Project Order from SAIL for 2 MW System
Prostarm Info Systems Limited has received a Letter of Acceptance (LOA) from Steel Authority of India Limited (SAIL) for a 2 MW Roof Top Solar PV project. The contract is valued at INR 6.71 Crores and involves the supply, installation, and commissioning of the system across various plant buildings. The project is scheduled for execution over a 12-month period. This domestic order from a major PSU strengthens the company's portfolio in the renewable energy sector.
Key Highlights
Awarded a 2 MW (AC) Roof Top Solar PV System project by SAIL
Total contract value is approximately INR 6.71 Crores
Execution timeline for the project is 12 months
Scope includes supply, installation, and commissioning at various plant buildings
👀 What to Watch
Investors should view this as a positive development that enhances the company's order book and credibility with large PSUs. Monitor the timely execution of the project and its impact on upcoming quarterly margins.
Blue Star Launches 125 New AC Models for 2026, Targets 1.8M Unit Capacity
Blue Star has unveiled a comprehensive range of 125 new Room Air Conditioner models for the 2026 summer season, all compliant with the latest BEE energy standards. The company is scaling its manufacturing capacity from 1.4 million to 1.8 million units to meet a projected industry demand of 30 million units by FY30. Key product innovations include 'Super Energy-Efficient ACs' with an ISEER of 6.25 and heavy-duty models capable of cooling at 56°C. The expansion strategically targets high-growth Tier 3-5 markets and includes a robust range of commercial refrigeration solutions for sectors like healthcare and quick commerce.
Key Highlights
Launched 125 new Room AC models including the premium 'Iconia' range and 'Super Energy-Efficient' units with 6.25 ISEER.
Manufacturing capacity currently at 1.4 million units, with scalability up to 1.8 million units across three plants.
Distribution network expanded to 900 towns with over 10,000 retail outlets and 2,100 service partners.
Heavy-duty ACs designed to maintain full cooling capacity at 43°C and operate in temperatures up to 56°C.
Strategic focus on Tier 3, 4, and 5 markets to capture first-time buyers and replacement demand.
👀 What to Watch
Investors should monitor market share gains in under-penetrated Tier 3-5 cities and the successful ramp-up of the Sri City facility. The stock remains a strong play on India's rising cooling demand and energy efficiency trends.
Blue Star Seeks Shareholder Approval for Key Leadership Appointments and Re-appointments
Blue Star Limited has issued a postal ballot notice to seek shareholder approval for three significant board positions. The company proposes the re-appointment of Mr. B Thiagarajan as Managing Director until May 2027 and the appointment of Mr. Mohit Sud as Executive Director for the Unitary Cooling Products Group for a five-year term. Additionally, Mr. M S Unnikrishnan is proposed as an Independent Director for a five-year term effective January 2026. These appointments are intended to ensure leadership continuity and functional expertise in core business segments.
Key Highlights
Re-appointment of Mr. B Thiagarajan as Managing Director from April 1, 2026, to May 24, 2027.
Appointment of Mr. Mohit Sud as Executive Director for a 5-year term starting April 1, 2026.
Appointment of Mr. M S Unnikrishnan as Independent Director for a 5-year term from Jan 29, 2026, to Jan 28, 2031.
Remote e-voting period scheduled from March 2, 2026, to March 31, 2026.
Final results of the postal ballot to be declared on or before April 2, 2026.
👀 What to Watch
Investors should note the leadership continuity in the Managing Director role and the addition of specialized leadership for the cooling products group. No immediate action is required as these are standard governance procedures to formalize management structure.
Prostarm Secures INR 13.43 Crore Solar Project from South Eastern Railway
Prostarm Info Systems Limited has received a Letter of Acceptance from South Eastern Railway for a solar power plant project. The contract is valued at INR 13.43 Crores and involves the supply, installation, and erection of the plant at SRC Jurisdiction (Phase 2). The project is scheduled for completion within 12 months and includes a 5-year comprehensive maintenance contract. This order strengthens the company's order book and highlights its growing footprint in the renewable energy sector.
Key Highlights
Awarded a contract worth INR 13.43 Crores by South Eastern Railway
Scope includes supply, installation, and erection of a solar power plant
Project execution timeline is 12 months from the date of LOA
Includes a 5-year Comprehensive Maintenance Contract (CMC) post-installation
The contract was secured in the normal course of business for Phase 2 of the SRC Jurisdiction
👀 What to Watch
Investors should view this as a positive development for revenue visibility and track the company's execution efficiency over the 12-month period. The 5-year maintenance component provides a small but steady stream of recurring service income.
Star Cement Subsidiary Starts Commercial Production at 2.0 MTPA Grinding Unit in Assam
Star Cement Limited's subsidiary, Star Cement North East Limited, has successfully commenced commercial production at its new grinding unit in Cachar, Assam, as of February 20, 2026. The new facility adds a substantial 2.0 MTPA (Million Tonnes Per Annum) to the company's existing production capacity. This expansion is strategically located to serve the high-demand Northeast Indian market. The operationalization of this unit is expected to drive volume growth and enhance the company's regional market share in the near term.
Key Highlights
Commencement of commercial production at a new 2.0 MTPA grinding unit in Cachar, Assam.
The project was executed through the subsidiary company, Star Cement North East Limited.
Operations officially began on February 20, 2026, following successful setup.
The expansion significantly boosts the company's total cement grinding capacity in its core Northeast market.
👀 What to Watch
Investors should consider this a positive development for long-term growth as it increases production capacity by 2.0 MTPA. Monitor the next few quarterly results to see the impact of this new capacity on revenue and EBITDA margins.
IndoStar Q3 PAT at ₹8.25 Cr; 9M Profit Surges to ₹554 Cr on NHFPL Divestment Gain
IndoStar Capital Finance reported a standalone Profit After Tax (PAT) of ₹8.25 crore for Q3 FY26, down from ₹11.41 crore in the previous year's corresponding quarter. The nine-month (9M FY26) PAT reached a significant ₹554.16 crore, primarily due to a one-time exceptional gain of ₹1,175.95 crore from the sale of its subsidiary, Niwas Housing Finance. Total revenue from operations for the quarter stood at ₹346.33 crore, showing a slight decline year-on-year. The company also accounted for a ₹4.8 crore impact on employee expenses following the notification of new Government Labour Codes.
Key Highlights
Standalone PAT for Q3 FY26 stood at ₹8.25 crore compared to ₹11.41 crore in Q3 FY25.
Exceptional gain of ₹1,175.95 crore recorded in 9M FY26 from the divestment of Niwas Housing Finance (NHFPL).
Finance costs decreased to ₹137.13 crore in Q3 FY26 from ₹192.98 crore in the same quarter last year.
Impairment on financial instruments rose to ₹76.92 crore in Q3 FY26 from ₹47.94 crore YoY.
Stressed loans with an aggregate principal of ₹343.66 crore were transferred to ARCs during the nine-month period.
👀 What to Watch
Investors should monitor how the company deploys the substantial capital gains from the NHFPL sale to drive growth in its core lending segments. While operational profitability remains modest, the reduction in finance costs and a cleaner balance sheet post-ARC transfers are positive signs for long-term stability.
